Serum glial fibrillary acidic protein in natalizumab-treated relapsing-remitting multiple sclerosis: An alternative to neurofilament lightMark HJ Wessels, Charlotte E. Teunissen, Zoé L. E. van Kempen et al.|Multiple Sclerosis Journal|2023Cited by 17
Reliability of serum neurofilament light and glial fibrillary acidic protein for detecting disease activity upon discontinuation of first-line disease-modifying therapy in stable multiple sclerosis (DOT-MS)Wing Hee Fung, Eva Strijbis, Jop Mostert et al.|Journal of Neurology|2025Cited by 4